Eli Lilly reported positive topline results from TRANSCEND-T2D-1, the first Phase 3 trial of retatrutide in type 2 diabetes. At 40 weeks, retatrutide lowered A1C by 1.7% to 2.0% across doses, while the 12 mg dose produced average weight loss of 36.6 pounds, or 16.8%. Lilly also said weight loss had not plateaued by the end of the trial.
What makes this readout more interesting is how diabetes-focused clinicians are reacting to it. In their latest discussion of the news on the Diabetes Dialogue podcast, Diana Isaacs and Natalie Bellini said the combination of large A1C reductions and substantial weight loss stands out because these results came from a type 2 diabetes population, where weight loss has historically been harder to achieve than in obesity-only trials.
They also pointed to the baseline A1C of 7.9% as an important detail. Natalie Bellini noted that A1C reductions of about 2% are often seen in people starting much higher, which makes these results more striking. She also said the trial population looked closer to the kind of patient seen in everyday practice, with an average starting weight of 213 pounds and an average BMI of 35.8.
Tolerability will still matter. Lilly said the most common adverse events were nausea, diarrhea, and vomiting, mostly during dose escalation. Dysesthesia, an unpleasant abnormal skin sensation such as burning or tingling, was also reported. Discontinuation rates due to adverse events remained relatively low at 2.2% to 5.1% across retatrutide doses. Isaacs called that low discontinuation range another encouraging part of the update.
Industry coverage added a useful note of caution. Analysts described retatrutide as a potentially differentiated option for people with type 2 diabetes when weight loss is a major treatment goal, but cross-trial comparisons remain limited and should be treated carefully.
Detailed results are expected at the American Diabetes Association's Scientific Sessions in June. For now, the topline message is straightforward: retatrutide is drawing attention not just because the numbers were strong, but because they were strong in a type 2 diabetes population that looks closer to the patients clinicians actually see.
Sources
Diabetes Dialogue Podcast
Lilly Press Release
Fierce Biotech Coverage
